سبحان دارو
دسبحان | Stocks - Tehran Stock Exchange (TSE)
داروهای شیمیایی و گیاهی
Sector:
داروهای شیمیایی و گیاهی
Market Type:
Stocks
Status:
Authorized
Last Price: 21,720 1.99
Close Price: 21,570
Income Statement
AGM
Interim
2026/05/13 Fiscal Year 2025/12/2112 Month | 2025/03/15 Fiscal Year 2024/12/2012 Month | 2024/05/19 Fiscal Year 2024/03/1912 Month | ||
|---|---|---|---|---|
Revenue from Services & Sales | 30.02 Trillion | 13.433 Trillion | 19.828 Trillion | |
Total Revenues | 30.02 Trillion | 13.433 Trillion | 19.828 Trillion | |
Cost of Goods Sold | 15.915 Trillion | 8.231 Trillion | 11.482 Trillion | |
Gross Profit | 14.104 Trillion | 5.202 Trillion | 8.346 Trillion | |
General & Administrative Expenses | 1.606 Trillion | 801.495 Billion | 792.049 Billion | |
Net Operating Income & Expenses | -396.042 Billion | -155.806 Billion | 31.352 Billion | |
Operating Profit (Loss) | 12.102 Trillion | 4.245 Trillion | 7.586 Trillion | |
Profit Before Tax | 6.042 Trillion | 2.9 Trillion | 5.719 Trillion | |
Tax | 711.746 Billion | - | 917.345 Billion | |
Net Profit (Loss) After Tax | 5.331 Trillion | 2.9 Trillion | 4.802 Trillion | |
Retained Earnings at Beginning of Period | 2.751 Trillion | 4.635 Trillion | 3.7 Trillion | |
Approved Dividends — Prior Year AGM | -1.023 Trillion | -3.145 Trillion | -1.997 Trillion | |
Capital Decrease (Increase) from Accumulated Losses (Retained Earnings) | -52.688 Billion | -1.49 Trillion | -1.7 Trillion | |
Allocable Profit | 7.006 Trillion | 2.9 Trillion | 4.805 Trillion | |
Legal Reserve | 266.536 Billion | 149 Billion | 170 Billion | |
Approved Dividends — Current Year | 1.6 Trillion | 1.023 Trillion | 3.145 Trillion | |
Retained Earnings at End of Period | 5.14 Trillion | 1.728 Trillion | 1.49 Trillion |